COMMUNIQUÉS West-GlobeNewswire

Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with Native Markets, and Purchase of 150,000 Additional HYPE
04/12/2025
Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by the Company Partnership with Native Markets to Support Hyperliquid-Aligned USDH Stablecoin [...]
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
04/12/2025
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, [...]
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
04/12/2025
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans [...]
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
04/12/2025
Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to [...]
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
04/12/2025
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated [...]
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
04/12/2025
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months [...]
Tilray Releases the Ultimate 2025 Holiday Drink Gift Guide, Celebrating Seasonal Sips and Moments of Connection from Coast to Coast
04/12/2025
ATLANTA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and [...]
Philips reiterates timing of 2026 outlook
04/12/2025
December 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the [...]
Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine
04/12/2025
AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new biomarker data identifying a molecular signature that predicts [...]
McLaren Bay Region Raises the Bar on Emergency Department Communication with MEDI+SIGN
04/12/2025
BAY CITY, Mich., Dec. 04, 2025 (GLOBE NEWSWIRE) -- McLaren Bay Region has equipped its Emergency Department treatment rooms with MEDI+SIGN Digital Whiteboards and Door Displays to enhance the patient experience and [...]
USOSM Secures Partnership with Northern Virginia Oral, Maxillofacial & Implant Surgery
04/12/2025
IRVING, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial surgeons – has formalized a new [...]
BeautyHealth Releases Third Annual Skintuition Report
04/12/2025
Latest volume reveals how shifting consumer preferences are redefining modern aesthetics LONG BEACH, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial [...]
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
04/12/2025
Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz ® over treatment area of 240 cm 2 Completion of this study marks a key milestone towards a planned [...]
Anathapindika Health Enters Harvest Natural Foods
04/12/2025
The Detoxification Dietary Supplement Brand Is Officially in Another West Coast Brick-and-Mortar Location Fort Lauderdale, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Anathapindika Health sells a trio of groundbreaking [...]
New Study Shows Promising Advancement in Stroke Treatment That Aligns With the Philosophy Behind Anathapindika’s Detoxing Supplements
04/12/2025
Anathapindika’s Supplements Are Unique in Their Focus on Detoxification. Recent Research Surrounding Stroke Recovery Could Support Their Use as Natural Brain and Body Cleansing Agents. Fort Lauderdale, FL, Dec. 04, 2025 [...]
Marius Pharmaceuticals CEO Shalin Shah Invited to Speak at Landmark FDA Expert Panel on Testosterone Replacement Therapy for Men
04/12/2025
RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced that its Chief Executive Officer, Shalin Shah, will speak at the FDA Expert Panel on Testosterone Replacement Therapy for Men [...]
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
04/12/2025
Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 JERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or [...]
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
04/12/2025
Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates [...]
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
04/12/2025
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly [...]

Pages